Search - tctmd.com

Displaying 1 - 20 of 31

Sort: Relevancy | Date

News Daily News

Inclisiran Gains Indication as Stand-alone Therapy to Reduce LDL Cholesterol

Michael O'Riordan

August 06, 2025

News Daily News

Inclisiran Plus Usual Care Improves LDL Control in ACS: VICTORION-INCEPTION

Michael O'Riordan

June 04, 2025

News Daily News

Inclisiran Effective as Monotherapy for Lower-Risk Primary Prevention

Michael O'Riordan

May 07, 2025

News Daily News

ACC/AHA Release New Comprehensive ACS Guidelines

Todd Neale

February 27, 2025

News Daily News

Lp(a) Linked to Higher ASCVD Risks in Diverse Patient Groups

Michael O'Riordan

April 17, 2024

News Daily News

High-Risk ‘Clues’ Add Heft to Calcium Scores in Primary Prevention

Michael O'Riordan

February 29, 2024

News Daily News

No Safety Concerns Seen With Inclisiran in Large ORION Analysis

Michael O'Riordan

December 06, 2023

News Daily News

Rosuvastatin, Atorvastatin: Similar Efficacy in LODESTAR, Some Differing Signals

Yael L. Maxwell

October 19, 2023

News Daily News

High-risk Plaques in Nonculprit Lesions Tied to Worse Post-MI Outcomes

Caitlin E. Cox

September 18, 2023

News Daily News

LDL Control Remains Poor in CAD Patients: NHANES

Michael O'Riordan

July 05, 2023

News Daily News

Ezetimibe Plus Moderate-Dose Statins May Aid Compliance in the Elderly

Yael L. Maxwell

April 03, 2023

News Daily News

Don’t Just Prescribe a Statin—Measure and Control LDL, Say NLA, ASPC

Michael O'Riordan

March 01, 2023

News Daily News

Sustained LDL-Cholesterol Reductions With Inclisiran: ORION-3

Michael O'Riordan

January 16, 2023

News Daily News

Study Alleges Mortality Miscount in FOURIER Trial; TIMI Group Disagrees

Michael O'Riordan

January 05, 2023

News Daily News

Top General Cardiology and Prevention News of 2022

Michael O'Riordan

December 26, 2022

News Daily News

New on the Scene Nonstatin Drugs: Experts Provide Guidance

Caitlin E. Cox

August 31, 2022

News Daily News

Good News and Bad for High-Intensity Statin Use in ASCVD

Michael O'Riordan

May 05, 2022

News Daily News

Homozygous FH Diagnosis Often Comes Late, With Lackluster Care

Michael O'Riordan

February 10, 2022

News Daily News

TCTMD’s Top 10 Most Popular Stories for December 2021

Caitlin E. Cox

December 29, 2021

News Daily News

FDA Approves Inclisiran, a Twice-Yearly Injection to Lower LDL Levels

Michael O'Riordan

December 22, 2021

Advertisement

Inclisiran Gains Indication as Stand-alone Therapy to Reduce LDL Cholesterol

Inclisiran Plus Usual Care Improves LDL Control in ACS: VICTORION-INCEPTION

Inclisiran Effective as Monotherapy for Lower-Risk Primary Prevention

ACC/AHA Release New Comprehensive ACS Guidelines

Lp(a) Linked to Higher ASCVD Risks in Diverse Patient Groups

High-Risk ‘Clues’ Add Heft to Calcium Scores in Primary Prevention

No Safety Concerns Seen With Inclisiran in Large ORION Analysis

Rosuvastatin, Atorvastatin: Similar Efficacy in LODESTAR, Some Differing Signals

High-risk Plaques in Nonculprit Lesions Tied to Worse Post-MI Outcomes

LDL Control Remains Poor in CAD Patients: NHANES

Ezetimibe Plus Moderate-Dose Statins May Aid Compliance in the Elderly

Don’t Just Prescribe a Statin—Measure and Control LDL, Say NLA, ASPC

Sustained LDL-Cholesterol Reductions With Inclisiran: ORION-3

Study Alleges Mortality Miscount in FOURIER Trial; TIMI Group Disagrees

Top General Cardiology and Prevention News of 2022

New on the Scene Nonstatin Drugs: Experts Provide Guidance

Good News and Bad for High-Intensity Statin Use in ASCVD

Homozygous FH Diagnosis Often Comes Late, With Lackluster Care

TCTMD’s Top 10 Most Popular Stories for December 2021

FDA Approves Inclisiran, a Twice-Yearly Injection to Lower LDL Levels

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content